1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.

https://doi.org/10.3322/caac.21660

PMid:33538338 

2. Vartanian JG, Gross JL, Kowalski LP. Distant metastasis from head and neck cancer: role of surgical treatment. Curr Opin Otolaryngol Head Neck Surg. 2022;30:114-8.

https://doi.org/10.1097/MOO.0000000000000789

PMid:35255047 

3. Mittal A, Sharma A. Current status of systemic therapy in head and neck cancer. J Chemother. 2022;34:9-24.

https://doi.org/10.1080/1120009X.2021.1955201

PMid:34308772 

4. Belgioia L, Becherini C, Bacigalupo A, Bonomo P. Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand? Oral Oncol. 2022;127:105773.

https://doi.org/10.1016/j.oraloncology.2022.105773

PMid:35217401 

5. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-34.

https://doi.org/10.1084/jem.192.7.1027

PMid:11015443 PMCid:PMC2193311

6. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.

https://doi.org/10.1038/nm730

PMid:12091876 

7. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813-24.

https://doi.org/10.1093/intimm/dxm057

PMid:17606980 

8. Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC. The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int. 2014;111:665-73.

https://doi.org/10.3238/arztebl.2014.0665

PMid:25346356 PMCid:PMC4215084

9. Buchwald ZS, Schmitt NC. Immunotherapeutic Strategies for Head and Neck Cancer. Otolaryngol Clin North Am. 2021;54:729-42.

https://doi.org/10.1016/j.otc.2021.04.004

PMid:34116846 

10. Zhou L, Xu N, Shibata H, Saloura V, Uppaluri R. Epigenetic modulation of immunotherapy and implications in head and neck cancer. Cancer Metastasis Rev. 2021;40:141-52.

https://doi.org/10.1007/s10555-020-09944-0

PMid:33403469 PMCid:PMC7897200

11. Park R, Park JC. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer. Immunotherapy. 2021;13:931-40.

https://doi.org/10.2217/imt-2021-0048

PMid:34100301 

12. Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19:1338-50.

https://doi.org/10.1016/S1470-2045(18)30495-9

PMid:30213452 

13. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016;2:1346-53.

https://doi.org/10.1001/jamaoncol.2016.1051

PMid:27367787 

14. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254-63.

https://doi.org/10.1097/CCO.0000000000000290

PMid:27136138 

15. Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13:47.

https://doi.org/10.1186/s13045-020-00886-2

PMid:32393323 PMCid:PMC7216554

16. Markham A, Keam SJ. Camrelizumab: First Global Approval. Drugs. 2019;79:1355-61.

https://doi.org/10.1007/s40265-019-01167-0

PMid:31313098 

17. Chen X, Ma L, Wang X, Mo H, Wu D, Lan B, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med. 2019;16:173-81.

https://doi.org/10.20892/j.issn.2095-3941.2018.0172

PMid:31119058 PMCid:PMC6528453

18. Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21:832-42.

https://doi.org/10.1016/S1470-2045(20)30110-8

PMid:32416073 

19. Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clin Cancer Res. 2019;25:515-23.

https://doi.org/10.1158/1078-0432.CCR-18-2484

PMid:30348638 

20. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4:1721-28.

https://doi.org/10.1001/jamaoncol.2018.3923

PMid:30242316 PMCid:PMC6440712

21. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-68.

https://doi.org/10.1200/JCO.2017.77.6385

PMid:29442540 PMCid:PMC6481621